Search

Your search keyword '"Choy, Matthew C."' showing total 31 results
Start Over Author "Choy, Matthew C."
31 results on '"Choy, Matthew C."'

1. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Author

Choy, Matthew C, Li Wai Suen, Christopher F D, Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William R, Wright, Emily K, Taylor, Kirstin M, Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham, Garg, Mayur, Martin, Neal, van Langenberg, Daniel R, Ding, Nik S, Beswick, Lauren, Leong, Rupert W, Sparrow, Miles P, and De Cruz, Peter

Published
2024
Full Text
View/download PDF

8. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making

Author

Kabir, Misha, primary, Thomas-Gibson, Siwan, additional, Tozer, Phil J, additional, Warusavitarne, Janindra, additional, Faiz, Omar, additional, Hart, Ailsa, additional, Allison, Lisa, additional, Acheson, Austin G, additional, Atici, Semra Demirli, additional, Avery, Pearl, additional, Brar, Mantaj, additional, Carvello, Michele, additional, Choy, Matthew C, additional, Dart, Robin J, additional, Davies, Justin, additional, Dhar, Anjan, additional, Din, Shahida, additional, Hayee, Bu'Hussain, additional, Kandiah, Kesavan, additional, Katsanos, Konstantinos H, additional, Lamb, Christopher Andrew, additional, Limdi, Jimmy K, additional, Lovegrove, Richard E, additional, Myrelid, Pär, additional, Noor, Nurulamin, additional, Papaconstantinou, Ioannis, additional, Petrova, Dafina, additional, Pavlidis, Polychronis, additional, Pinkney, Thomas, additional, Proud, David, additional, Radford, Shellie, additional, Rao, Rohit, additional, Sebastian, Shaji, additional, Segal, Jonathan P, additional, Selinger, Christian, additional, Spinelli, Antonino, additional, Thomas, Kathryn, additional, Wolthuis, Albert, additional, and Wilson, Ana, additional

Published
2023
Full Text
View/download PDF

9. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making

Author

Kabir, Misha, Thomas-Gibson, Siwan, Tozer, Phil J., Warusavitarne, Janindra, Faiz, Omar, Hart, Ailsa, Allison, Lisa, Acheson, Austin G., Atici, Semra Demirli, Avery, Pearl, Brar, Mantaj, Carvello, Michele, Choy, Matthew C., Dart, Robin J., Davies, Justin, Dhar, Anjan, Din, Shahida, Hayee, BuHussain, Kandiah, Kesavan, Katsanos, Konstantinos H., Lamb, Christopher Andrew, Limdi, Jimmy K., Lovegrove, Richard E., Myrelid, Pär, Noor, Nurulamin, Papaconstantinou, Ioannis, Petrova, Dafina, Pavlidis, Polychronis, Pinkney, Thomas, Proud, David, Radford, Shellie, Rao, Rohit, Sebastian, Shaji, Segal, Jonathan P., Selinger, Christian, Spinelli, Antonino, Thomas, Kathryn, Wolthuis, Albert, Wilson, Ana, Kabir, Misha, Thomas-Gibson, Siwan, Tozer, Phil J., Warusavitarne, Janindra, Faiz, Omar, Hart, Ailsa, Allison, Lisa, Acheson, Austin G., Atici, Semra Demirli, Avery, Pearl, Brar, Mantaj, Carvello, Michele, Choy, Matthew C., Dart, Robin J., Davies, Justin, Dhar, Anjan, Din, Shahida, Hayee, BuHussain, Kandiah, Kesavan, Katsanos, Konstantinos H., Lamb, Christopher Andrew, Limdi, Jimmy K., Lovegrove, Richard E., Myrelid, Pär, Noor, Nurulamin, Papaconstantinou, Ioannis, Petrova, Dafina, Pavlidis, Polychronis, Pinkney, Thomas, Proud, David, Radford, Shellie, Rao, Rohit, Sebastian, Shaji, Segal, Jonathan P., Selinger, Christian, Spinelli, Antonino, Thomas, Kathryn, Wolthuis, Albert, and Wilson, Ana

Abstract

Background and Aims Inflammatory bowel disease colitis-associated dysplasia is managed with either enhanced surveillance and endoscopic resection or prophylactic surgery. The rate of progression to cancer after a dysplasia diagnosis remains uncertain in many cases and patients have high thresholds for accepting proctocolectomy. Individualised discussion of management options is encouraged to take place between patients and their multidisciplinary teams for best outcomes. We aimed to develop a toolkit to support a structured, multidisciplinary and shared decision-making approach to discussions about dysplasia management options between clinicians and their patients. Methods Evidence from systematic literature reviews, mixed-methods studies conducted with key stakeholders, and decision-making expert recommendations were consolidated to draft consensus statements by the DECIDE steering group. These were then subjected to an international, multidisciplinary modified electronic Delphi process until an a priori threshold of 80% agreement was achieved to establish consensus for each statement. Results In all, 31 members [15 gastroenterologists, 14 colorectal surgeons and two nurse specialists] from nine countries formed the Delphi panel. We present the 18 consensus statements generated after two iterative rounds of anonymous voting. Conclusions By consolidating evidence for best practice using literature review and key stakeholder and decision-making expert consultation, we have developed international consensus recommendations to support health care professionals counselling patients on the management of high cancer risk colitis-associated dysplasia. The final toolkit includes clinician and patient decision aids to facilitate shared decision-making.

Published
2023
Full Text
View/download PDF

15. 900 PREDICT UC: OPTIMISING INFLIXIMAB INDUCTION THERAPY FOR ACUTE SEVERE ULCERATIVE COLITIS - A RANDOMISED CONTROLLED TRIAL

Author

Choy, Matthew C., Suen, Christopher F. Li Wai, Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard G., Gorelik, Alexandra, Liew, Danny, Connell, William, Wright, Emily K., Taylor, Kirstin M., Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham L., Garg, Mayur, Martin, Neal, Van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert, Sparrow, Miles, and De Cruz, Peter

Published
2024
Full Text
View/download PDF

16. Su1760 CLINICAL AND ENDOSCOPIC REMISSION AT 3 MONTHS AFTER ACUTE SEVERE ULCERATIVE COLITIS IS PREDICTIVE OF MAINTENANCE THERAPY OUTCOMES AT 12 MONTHS - RESULTS FROM PREDICT UC

Author

Suen, Christopher F. Li Wai, Choy, Matthew C., Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard G., Gorelik, Alexandra, Liew, Danny, Connell, William, Wright, Emily K., Taylor, Kirstin M., Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham L., Garg, Mayur, Martin, Neal, Van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert, Sparrow, Miles, and De Cruz, Peter

Published
2024
Full Text
View/download PDF

23. Mo1876 – Expression of Cd69 on Peripheral Lymphocytes Predicts Treatment Response in Acute Severe Ulcerative Colitis

Author

Choy, Matthew C., primary, Yu, Jackie, additional, Congiu, Mario, additional, Pelpola, Prasangi, additional, Nigro, Julie, additional, Burder, Ronan, additional, Boyd, Kristy, additional, McGuckin, Michael A., additional, Corbett, Alexandra, additional, Kjer-Nielsen, Lars, additional, McCluskey, James, additional, Visvanathan, Kumar, additional, and De Cruz, Peter, additional

Published
2019
Full Text
View/download PDF

25. Mo1908 - Early Prediction of Steroid Failure in Acute Severe Ulcerative Colitis

Author

Choy, Matthew C., primary, Boyd, Kristy, additional, Burder, Ronan, additional, Gorelik, Alexandra, additional, Nallas, Ronnel, additional, Horvath, Jennifer, additional, Lam, Que, additional, Crinis, Nick, additional, van Langenberg, Daniel R., additional, Sparrow, Miles, additional, Connell, William, additional, Visvanathan, Kumar, additional, and De Cruz, Peter, additional

Published
2018
Full Text
View/download PDF

26. Mo1888 - Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis

Author

Choy, Matthew C., primary, Seah, Dean, additional, Faleck, David, additional, Shah, Shailja, additional, Khoury, Alex Al, additional, An, Yoon Kyo, additional, Radford-Smith, Graham L., additional, Bessissow, Talat, additional, Ford, Alexander C., additional, Dubinsky, Marla, additional, Yeomans, Neville, additional, and De Cruz, Peter, additional

Published
2018
Full Text
View/download PDF

27. Predicting response after infliximab salvage in acute severe ulcerative colitis

Author

Choy, Matthew C, primary, Seah, Dean, additional, Gorelik, Alexandra, additional, An, Yoon-Kyo, additional, Chen, Cheng-Yu, additional, Macrae, Finlay A, additional, Sparrow, Miles P, additional, Connell, William R, additional, Moore, Gregory T, additional, Radford-Smith, Graham, additional, Van Langenberg, Daniel R, additional, and De Cruz, Peter, additional

Published
2018
Full Text
View/download PDF

30. Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis.

Author

Li Wai Suen CFD, Seah D, Choy MC, and De Cruz P

Subjects
Humans, Acute Disease, Infliximab therapeutic use, C-Reactive Protein analysis, C-Reactive Protein metabolism, Prognosis, Colectomy, Gastrointestinal Agents therapeutic use, Treatment Outcome, Leukocyte L1 Antigen Complex analysis, Colitis, Ulcerative drug therapy, Severity of Illness Index
Abstract

Background: Acute severe ulcerative colitis (ASUC) is a medical emergency for which colectomy is required in patients who do not respond to rescue therapy. While previous studies have predominantly focused on predicting outcome to first-line corticosteroid therapy, there is a need to understand the factors associated with response to rescue therapies in order to improve clinical outcomes. We reviewed the evidence regarding factors associated with response to rescue therapy in adults with ASUC and identified future directions for research., Methods: A systematic search of the literature was conducted, and 2 reviewers independently assessed studies for inclusion., Results: Of 3509 records screened, 101 completed studies were eligible for inclusion. We identified 42 clinical, hematological, biochemical, endoscopic, or pharmacological factors associated with response to rescue therapy. Older age (≥50 years), thiopurine experience, and cytomegalovirus or Clostridioides difficile infection were associated with a higher risk of nonresponse to rescue therapy. Biochemical factors associated with poorer response included an elevated C-reactive protein (CRP) ≥30mg/L on admission, hypoalbuminemia and an elevated ratio of CRP to albumin. Severe endoscopic findings, including a Mayo endoscopic score of 3 or Ulcerative Colitis Endoscopic Index of Severity ≥5, portended poorer outcomes. The role of fecal calprotectin and therapeutic value of measuring infliximab drug levels in ASUC remain to be defined., Conclusions: Response to rescue therapy can be predicted by several specific factors, which would aid clinical decision-making. Existing and emerging factors should be integrated within predictive and prognostic models to help improve clinical outcomes., (© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

31. What to do when traditional rescue therapies fail in acute severe ulcerative colitis.

Author

Li Wai Suen CFD, Choy MC, and De Cruz P

Abstract

Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately 25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC are highly variable. Approximately 30% of patients do not respond to corticosteroids and up to 50% of patients do not respond to rescue therapy (infliximab or cyclosporin) and require emergency colectomy. Data are emerging on infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase inhibition as primary and sequential therapy. In this review, we outline contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results